Management of chronic hepatitis c in veterans: The potential of integrated care models

American Journal of Gastroenterology

Volumn 103, Issue 7, 2008, Pages 1810-1823

  Ho, Samuel B ^a   Groessl, Erik ^b   Dollarhide, Adrian ^b   Robinson, Shannon ^b   Kravetz, David ^b   Dieperink, Eric ^b  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; METHADONE; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ANTIVIRAL THERAPY; CLINICAL TRIAL; COGNITIVE THERAPY; COMBINATION CHEMOTHERAPY; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DRUG CONTRAINDICATION; DRUG DEPENDENCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GENOTYPE; HEALTH CARE PERSONNEL; HEALTH CARE QUALITY; HEPATITIS C; HUMAN; LIFESTYLE MODIFICATION; MENTAL DISEASE; MONOTHERAPY; MORBIDITY; MORTALITY; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT SATISFACTION; PRIORITY JOURNAL; REVIEW; SUBSTANCE ABUSE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VETERAN; ADDICTION; MENTAL HEALTH SERVICE; PATIENT CARE; THEORETICAL MODEL; UNITED STATES;

HEPATITIS C, CHRONIC; HUMANS; MENTAL HEALTH SERVICES; MODELS, THEORETICAL; PATIENT CARE TEAM; SUBSTANCE-RELATED DISORDERS; UNITED STATES; VETERANS;

EID: 50649116847     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2008.01877.x     Document Type: Review

References (100)

1. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705-14.
2. Edlin BR. Five million Americans infected with the hepatitis C virus: A corrected estimate [abstract]. Hepatology 2005;42:213A.
3. Dominitz JA, Boyko EJ, Koepsell TD, et al. Elevated prevalence of hepatitis C infection in users of United States veterans medical centers. Hepatology 2005;41:88-96.
4. Bini EJ. Hepatitis C in veterans. Curr Hepat Rep 2003;2:108-15.
5. Austin GE, Jensen B, Leete J, et al. Prevalence of hepatitis Cvirus seropositivity among hospitalizedUS veterans.Am J Med Sci 2000;319:353-9.
6. Mendenhall CL, Seeff L, Diehl AM, et al. Antibodies to hepatitis B virus and hepatitis C virus in alcoholic hepatitis and cirrhosis: Their prevalence and clinical relevance. The VA Cooperative Study Group (No. 119). Hepatology 1991;14:581-9.
7. Mendenhall CL, Moritz T, Rouster S, et al. Epidemiology of hepatitis C among veterans with alcoholic liver disease. TheVACooperative StudyGroup 275.AmJGastroenterol 1993;88:1022-6.
8. Rosman AS, Paronetto F, Galvin K, et al. Hepatitis C virus antibody in alcoholic patients. Association with the presence of portal and/or lobular hepatitis. Arch Intern Med 1993;153:965-9.
9. Pham D, Walshe D, Montgomery J, et al. Seroepidemiology of hepatitis C and B in an urban VA medical center. Hepatology 1994;20:236A.
10. Staples CT Jr, Rimland D, Dudas D. Hepatitis C in the HIV (human immunode?ciency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): The effect of coinfection on survival. Clin Infect Dis 1999;29:150-4.
11. Cheung RC. Epidemiology of hepatitis C virus infection in American veterans. Am J Gastroenterol 2000;95:740-7.
12. BriggsME, Baker C, Hall R, et al. Prevalence and risk factors for hepatitis C virus infection at an urban veterans administration medical center. Hepatology 2001;34:1200-5.
13. Brau N, Bini EJ, Shahidi A, et al. Prevalence of hepatitis C and coinfection with HIV among United States veterans in the New York City metropolitan area. Am J Gastroenterol 2002;97:2071-8.
14. Roselle GA, Danko LH, Kralovid SM, et al. National hepatitis C surveillance day in the Veterans Health Administration of the Department of Veterans Affairs. Mil Med 2002;167:756-9.
15. Cheung RC, Hanson AK, Maganti K, et al. Viral hepatitis and other infectious diseases in a homeless population. J Clin Gastroenterol 2002;34:476-80.
16. Davis GL, Albright JE, Cook SF, et al. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003;9:331-8.
17. Wong JB, McQuillan GM, McHutchison JG, et al. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000;90:1562-9.
18. McHutchison JG, Bacon BR. Chronic hepatitis C: An age wave of disease burden. Am JManag Care 2005;11:S286-95; quiz S307-11.
19. McHutchison JG, Bartenschlager R, Patel K, et al. The face of future hepatitis C antiviral drug development: Recent biological and virologic advances and their translation to drug development and clinical practice. J Hepatol 2006;44:411-21.
20. Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: A retrospective study. Hepatology 2007;45:579-87.
21. Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced ?brosis. Ann InternMed 2007;147:677-84.
22. National Hepatitis C Program [VHA directive 2001-009]. Available at: http://www.hepatitis.va.gov/vahep?page=prin-va-01. Accessed October 1, 2007.
23. Standards and accountability could improve hepatitis C screening and testing performance. Testimony before the Subcommittee on National Security, Veterans Affairs, and international Relations, Committee on Government Reform, House of Representatives, June 2001. Washington, DC: US General Accounting Of?ce. http://www.gao.gov/newitems/doi807t.pdf.
24. Butt AA, Justice AC, Skanderson M, et al. Rate and predictors of treatment prescription for hepatitis C. Gut 2007;56:385-9.
25. National Hepatitis C Case Registry. Ever ?lled outpatient prescription for an anti-hepatitis C Medication and in care in FY 2004-2006, Public Health Strategic Health Care Group, Department of Veterans Affairs: Washington DC. Available at: http://vaww.hepatitis.va.gov/vahep?page=prin-cqm-01#S2X or http://www.hepatitis.va.gov. Accessed October 1, 2007.
26. El-Serag HB. Translational research: The study of community effectiveness in digestive and liver disorders. Gastroenterology 2007;132:8-10.
27. Muir AJ, Provenzale D. A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection. J Clin Gastroenterol 2002;34:268-71.
28. Cawthorne CH, Rudat KR, Burton MS, et al. Limited success of HCV antiviral therapy in United States veterans. Am J Gastroenterol 2002;97:149-55.
29. Rowan PJ, Tabasi S, Abdul-Latif M, et al. Psychosocial factors are the most common contraindications for antiviral therapy at initial evaluation in veterans with chronic hepatitis C. J Clin Gastroenterol 2004;38:530-4.
30. Butt AA, Wagener M, Shakil AO, et al. Reasons for nontreatment of hepatitis C in veterans in care. J Viral Hepat 2005;12:81-5.
31. Tavakoli-Tabasi S, Rowan P, Abdul-Latif M, et al. Utility of a depression score to predict candidacy for hepatitis C virus therapy in veterans:Aprospective longitudinal study. Aliment Pharmacol Ther 2005;21:235-42.
32. Bini EJ, Brau N, Currie S, et al. Prospective multicenter study of eligibility for antiviral therapy among 4084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol 2005;100:1772-9.
33. Cheung RC, Cunningham BA, Cooper AD. Effectiveness of a screening program for hepatitis C. Dig Dis Sci 2006;51:976-81.
34. Chainuvati S, Khalid SK, Kancir S, et al. Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders. J Viral Hepat 2006;13:235-41.
35. Falck-YtterY,Kale H,Mullen KD, et al. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002;136:288-92.
36. Yawn BP, Wollan P, Gazzuola L, et al. Diagnosis and 10-year follow-up of a community-based hepatitis C cohort. J Fam Pract 2002;51:135-40.
37. Rocca LG, Yawn BP, Wollan P, et al. Management of patients with hepatitis C in a community population: Diagnosis, discussions, and decisions to treat. Ann Fam Med 2004;2:116-24.
38. Morrill JA, Shrestha M, Grant RW. Barriers to the treatment of hepatitis C. Patient, provider, and system factors. J Gen Intern Med 2005;20:754-8.
39. Evon DM, Verma A, Dougherty KA, et al. High deferral rates and poorer treatment outcomes for HCV patients with psychiatric and substance use comorbidities. Dig Dis Sci 2007;52:3251-3.
40. Shatin D, Schech SD, Patel K, et al. Population-based hepatitis C surveillance and treatment in a national managed care organization. Am J Manag Care 2004;10:250-6.
41. Morelli J, Kim CY, Willner IR. U.S. veterans' experience with rebetron in a nonstudy environment: Success or failure? Am J Gastroenterol 2002;97:2379-82.
42. Nguyen HA, Miller AI, Dieperink E, et al. Spectrum of disease in U.S. veteran patients with hepatitis C. Am J Gastroenterol 2002;97:1813-20.
43. Knott A, Dieperink E, Willenbring ML, et al. Integrated psychiatric/medical care in a chronic hepatitis C clinic: Effect on antiviral treatment evaluation and outcomes. Am J Gastroenterol 2006;101:2254-62.
44. Backus LI, Boothroyd DB, Phillips BR, et al. Predictors of response of U.S. veterans to treatment for the hepatitis C virus. Hepatology 2007;46:37-47.
45. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
46. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001;358:958-65.
47. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitisC:Arandomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.
48. Lee SS, Bain VG, Peltekian K, et al. Treating chronic hepatitis C with pegylated interferon alpha-2a (40 kD) and ribavirin in clinical practice. Aliment Pharmacol Ther 2006;23:397-408.
49. Jacobson IM, Brown RS, Freilich B, et al. Weight-based ribavirin dosing increases sustained viral response in patients with chronic hepatitis C: Final results of the WIN-R study, a US community based trial. Hepatology 2005;42:749A.
50. Getachew Y, Browning JD, Prebis M, et al. Combination therapy for the treatment of hepatitis C in the veteran population: Higher than expected rates of therapy discontinuation. Aliment Pharmacol Ther 2004;20:629-36.
51. El-Serag HB, Kunik M, Richardson P, et al. Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology 2002;123:476-82.
52. FiremanM, Indest DW, Blackwell A, et al. Addressing trimorbidity (hepatitisC, psychiatric disorders, and substance use): The importance of routine mental health screening as a component of a comanagementmodel of care. Clin Infect Dis 2005;40(Suppl 5):S286-91.
53. Monto A, Patel K, Bostrom A, et al. Risks of a range of alcohol intake on hepatitis C-related ?brosis. Hepatology 2004;39:826-34.
54. Lehman CL, Cheung RC. Depression, anxiety, posttraumatic stress, and alcohol-related problems among veterans with chronic hepatitis C. Am J Gastroenterol 2002;97:2640-6.
55. Yovtcheva SP, Rifai MA, Moles JK, et al. Psychiatric comorbidity among hepatitis C-positive patients. Psychosomatics 2001;42:411-5.
56. Ho SB, Nguyen H, Tetrick LL, et al. In?uence of psychiatric diagnoses on interferon-alpha treatment for chronic hepatitis C in a veteran population. Am J Gastroenterol 2001;96:157-64.
57. Dieperink E, Ho SB, Thuras P, et al. A prospective study of neuropsychiatric symptoms associated with interferon alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 2003;44:104-12.
58. Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alpha and ribavirin in psychiatric risk groups. Hepatology 2003;37:443-51.
59. NIH, National Institutes of Health consensus development conference panel statement: Management of hepatitis C. Hepatology 1997;26(Suppl 1):2S-10S.
60. Dieperink E, Leskela J, Dieperink ME, et al. The effect of pegylated interferon-alpha-2b and ribavirin on posttraumatic stress disorder symptoms. Psychosomatics 2008 (in press).
61. Schaefer M, Hinzpeter A, Mohmand A, et al. Hepatitis C treatment in "dif?cult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: Response and psychiatric side effects. Hepatology 2007;46:991-8.
62. Sylvestre DL, Litwin AH, Clements BJ, et al. The impact of barriers to hepatitis C virus treatment in recovering heroin usersmaintained onmethadone. J SubstAbuseTreat 2005;29:159-65.
63. Mauss S, Berger F, Goelz J, et al. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 2004;40:120-4.
64. Huckans MS, Loftis JM, Blackwell AD, et al. Interferon alpha therapy for hepatitis C: Treatment completion and response rates among patients with substance use disorders. Subst Abuse Treat Prev Policy 2007;2:4.
65. Robaeys G, Buntinx F. Treatment of hepatitis C viral infections in substance abusers. Acta Gastroenterol Belg 2005;68:55-67.
66. Robaeys G, Van Vlierberghe H, Mathei C, et al. Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. Eur J Gastroenterol Hepatol 2006;18:159-66.
67. Backmund M, Meyer K, Von Zielonka M, et al. Treatment of hepatitis C infection in injection drug users. Hepatology 2001;34:188-93.
68. Guadagnino V, Trotta MP, Montesano F, et al. Effectiveness of a multi-disciplinary standardized management model in the treatment of chronic hepatitis C in drug addicts engaged in detoxi?cation programmes. Addiction 2007;102:423-31.
69. Dalgard O. Follow-up studies of treatment for hepatitis C virus infection among injection drug users. Clin Infect Dis 2005;40(Suppl 5):S336-8.
70. Anand BS, Currie S, Dieperink E, et al. Alcohol use and treatment of hepatitis C virus: Results of a national multicenter study. Gastroenterology 2006;130:1607-16.
71. NIH, National Institutes of Health consensus development conference statement: Management of hepatitis C: 2002. Hepatology 2002;36:S3-S15.
72. Yee HS, Currie SL, Darling JM, et al. Management and treatment of hepatitis C viral infection: Recommendations from the Department of Veterans Affairs Hepatitis C Resource Center program and the National Hepatitis C Program of?ce. Am J Gastroenterol 2006;101:2360-78.
73. Willenbring ML. Integrating care for patients with infectious, psychiatric, and substance use disorders: Concepts and approaches. AIDS 2005;19(Suppl 3):S227-37.
74. Ouwens M, Wollersheim H, Hermens R, et al. Integrated care programmes for chronically ill patients: A review of systematic reviews. Int J Qual Health Care 2005;17:141-6.
75. Soto TA, Bell J, Pillen MB. Literature on integrated HIV care: A review. AIDS Care 2004;16(Suppl 1):S43-55.
76. Kresina TF, Khalsa J, Cesari H, et al. Hepatitis C virus infection and substance abuse:Medicalmanagement and developing models of integrated care - an introduction. Clin Infect Dis 2005;40(Suppl 5):S259-85.
77. Kresina TF, Bruce RD, Cargill VA, et al. Integrating care for hepatitis C virus (HCV) and primary care for HIV for injection drug users coinfected with HIV and HCV. Clin Infect Dis 2005;41(Suppl 1):S83-8.
78. Lucas GM, Mullen BA, Weidle PJ, et al. Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups. Clin Infect Dis 2006;42:1628-35.
79. McCance-Katz EF, Gourevitch MN, Arnsten J, et al. Modi?ed directly observed therapy (MDOT) for injection drug users with HIV disease. Am J Addict 2002;11:271-8.
80. Gilbody S, Whitty P, Grimshaw J, et al. Educational and organizational interventions to improve the management of depression in primary care: A systematic review. JAMA 2003;289:3145-51.
81. Dobscha SK, Corson K, Hickam DH, et al. Depression decision support in primary care: A cluster randomized trial. Ann Intern Med 2006;145:477-87.
82. Rubenstein LV. Improving care for depression: There' s no free lunch. Ann Intern Med 2006;145:544-6.
83. Druss BG, Rohrbaugh RM, Levinson CM, et al. Integrated medical care for patients with serious psychiatric illness: A randomized trial. Arch Gen Psychiatry 2001;58:861-8.
84. Saxon AJ,Malte CA, Sloan KL, et al. Randomized trial of onsite versus referral primary medical care for veterans in addictions treatment. Med Care 2006;44:334-42.
85. Willenbring ML, Olson DH. A randomized trial of integrated outpatient treatment formedically ill alcoholicmen. Arch Intern Med 1999;159:1946-52.
86. Lieber CS, Weiss DG, Groszmann R, et al. I. Veterans Affairs Cooperative Study of polyenylphosphatidyl-choline in alcoholic liver disease: Effects on drinking behavior by nurse/physician teams. Alcohol Clin Exp Res 2003;27:1757-64.
87. Bertholet N, Daeppen JB, Wietlisbach V, et al. Reduction of alcohol consumption by brief alcohol intervention in primary care: Systematic review and meta-analysis. Arch Intern Med 2005;165:986-95.
88. Willenbring M, Dieperink E, Heit S, et al. Response to a brief intervention in heavy alcohol users with hepatitis C. Alcohol Clin Exp Res 2005;29:75A.
89. Groessl EJ, Gifford AL, Kaplan RM. A qualitative study of veterans with hepatitis C: Adapting a self-management intervention, in Annual Meeting of the Society for Behavioral Medicine. 2005: Boston, MA.
90. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patientswith chronic hepatitisC.Gastroenterology 2002;123:1061-9.
91. Raison C, Demetrashvili M, Capuron L, et al. Neuropsy-chiatric adverse effects of interferon-alpha: Recognition and management. CNS Drugs 2005;19:105-23.
92. Gross J, Johnson S, Kwo P, et al. Double-dose peginterferon alpha-2b with weight-based ribavirin improves response for interferon/ribavirin non-responders with hepatitis C: Final results of "Renew". Hepatology 2005;24:(Suppl 1):219A-20A.
93. Berg T, von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: Comparing 48 versus 72 weeks of peginterferon-alpha-2a plus ribavirin. Gastroenterology 2006;130:1086-97.
94. Sanchez-Tapias JM, Diago M, Escartin P, et al. Peginterferon-alpha2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006;131:451-60.
95. Bacon B, Regev A, Ghalib RH, et al. The Direct Trial (daily-dose consensus interferon and ribavirin: Ef?cacy of combined therapy): Treatment of nonresponders to previous pegylated interferon plus ribavirin: Sustained virologic response data. Hepatology 2007;46:311A.
96. Barbaro G, Barbarini G. Consensus interferon for chronic hepatitis C patients with genotype 1 who failed to respond to, or relapsed after, interferon alpha-2b and ribavirin in combination: An Italian pilot study. Eur J Gastroenterol Hepatol 2002;14:477-83.
97. Bocher W, Schuchmann M, Link R, et al. Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy. Liver Int 2006;26:319-25.
98. Cornberg M, Hadem J, Herrmann E, et al. Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: A randomized open-label pilot study. J Hepatol 2006;44:219-301.
99. Falck-YtterY,KaleH,MullenKD, et al. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002;136:288-92.
100. Groom H, Dieperink E, Nelson DB, et al. Outcomes of a hepatitis C screening program at a large urban VA medical center. J Clin Gastroenterology 2008;42:97-106.